user

Development of anti-HER2 monoclonal antibodies for gastric cancer

被引：0
|
作者：
Nanamiya, Ren [1 ]
Suzuki, Hiroyuki [2 ]
Kato, Yukinari [1 ,2 ]
机构：
[1] Tohoku Univ, Dept Antibody Drug Dev, Grad Sch Med, Sendai, Miyagi, Japan
[2] Tohoku Univ, Dept Mol Pharmacol, Grad Sch Med, Sendai, Miyagi, Japan
来源：
CANCER SCIENCE | 2023年 / 114卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-1164
引用
收藏
页码：589 / 589
页数：1
相关论文
共 50 条
  • [21] Handling of anti-HER2 antibodies, trastuzumab and pertuzumab, in patients with HER2-positive breast cancer
    Araki, Kazuhiro
    Ito, Yoshinori
    ANNALS OF ONCOLOGY, 2015, 26 : 48 - 48
  • [22] Anti-HER2 Cancer Therapy and Cardiotoxicity
    Babar, Tania
    Blomberg, Christopher
    Hoffner, Eileen
    Yan, Xinhua
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (30) : 4911 - 4919
  • [23] Anti-HER2 immunopet for the detection of cancer
    Robinson, M
    Shaller, C
    Doss, M
    Narayanan, D
    Marks, J
    Adler, L
    Trotter, DG
    Adams, G
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2004, 19 (04) : 517 - 517
  • [24] Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates
    Wong, Deborah J. L.
    Hurvitz, Sara A.
    ANNALS OF TRANSLATIONAL MEDICINE, 2014, 2 (12)
  • [25] Mechanism of action of anti-HER2 monoclonal antibodies:: Scientific update on trastuzumab and 2C4
    Albanell, J
    Codony, J
    Rovira, A
    Mellado, B
    Gascón, P
    NEW TRENDS IN CANCER FOR THE 21ST CENTURY, 2003, 532 : 253 - 268
  • [26] ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-Her2 monoclonal antibodies
    Kita, Y
    Tseng, J
    Horan, T
    Wen, J
    Philo, J
    Chang, D
    Ratzkin, B
    Pacifici, R
    Brankow, D
    Hu, S
    Luo, Y
    Wen, DZ
    Arakawa, T
    Nicolson, M
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 226 (01) : 59 - 69
  • [27] High affinity promotes more effective ADCC by anti-HER2/neu monoclonal antibodies.
    Tang, Y.
    Alpaugh, K.
    Lou, J.
    Litwin, S.
    Shaller, C.
    Adams, G.
    Marks, J.
    Weiner, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 109S - 109S
  • [28] Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies?
    Graziano, Vincenzo
    Scognamiglio, Maria Teresa
    Zilli, Marinella
    Giampietro, Jamara
    Vici, Patrizia
    Natoli, Clara
    Grassadonia, Antonino
    CANCER BIOLOGY & THERAPY, 2015, 16 (12) : 1704 - 1709
  • [29] A case with HER2-overexpressing breast cancer completely responded to humanized anti-HER2 monoclonal antibody
    Ohta, M
    Tokuda, Y
    Suzuki, Y
    Kubota, M
    Watanabe, T
    Fujii, H
    Sasaki, Y
    Niwa, T
    Makuuchi, H
    Tajima, T
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2001, 31 (11) : 553 - 556
  • [30] Androgen receptors are highly expressed in HER2-positive breast cancers that achieve pCR to anti-HER2 monoclonal antibodies
    Pellegrino, Benedetta
    Campanini, Nicoletta
    Boggiani, Daniela
    Zanoni, Daniele
    Sikokis, Angelica
    Missale, Gabriele
    Maglietta, Giuseppe
    Frassoldati, Antonio
    Michiara, Maria
    Silini, Enrico Maria
    Musolino, Antonino
    CANCER RESEARCH, 2021, 81 (04)
12345